<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Ulcerative Colitis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-12-09">December 9, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Elena</forename><surname>Sonnenberg</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Britta</forename><surname>Siegmund</surname></persName>
							<email>britta.siegmund@charite.de</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">Medizinische Klinik für Gastroenterologie</orgName>
								<address>
									<settlement>Infektiologie, Rheumatologie</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Medizinische Klinik für Gastroenterologie</orgName>
								<address>
									<settlement>Infektiologie, Rheumatologie</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin Hindenburgdamm 30</addrLine>
									<postCode>DE-12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Ulcerative Colitis</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-12-09">December 9, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">57469350D1E1C0A15DE1CF27199C32F0</idno>
					<idno type="DOI">10.1159/000452621</idno>
					<note type="submission">Received: August 15, 2016 Accepted after revision: October 15, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:21+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is chronically present in patients throughout their lives.</s><s>Hence, the chronic nature of the disease invariably requires continuous medical treatment.</s><s>Advances in medical therapy over the last decades and current developments offer increasing options and are closely associated with a better life quality in patients.</s><s>Summary: Recent developments in understanding the pathogenesis of UC are discussed.</s><s>The current standard therapeutic regimens are outlined and recent developments and upcoming strategies introduced.</s><s>Key Points: (1) Environmental factors that are yet to be defined contribute to the pathogenesis of UC. (2) An accelerated step-up therapy represents the current standard in UC. (3) Anti-integrins represent the most recently introduced pharmacological class in the therapy of UC. (4) Novel strategies including Janus kinase inhibitors are in the near future.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>understood.</s><s>Hence, currently, there is no cure to treat this condition.</s><s>While over 200 risk loci have been identified for inflammatory bowel diseases, only about one fourth of disease occurrences can be explained genetically <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref> .</s><s>Considering in parallel the increasing incidence of inflammatory bowel diseases over the last decades, it is more likely that changes in our environment contribute to this increase <ref type="bibr" target="#b2">[3]</ref> .</s><s>Although not entirely deciphered, environmentally induced changes in our intestinal microbiota composition can be presumed to play a significant role.</s><s>Experimental data strongly suggest that, in particular, the intestinal microbiota that is present early in life engraves the mucosal immune system, thus causing intestinal homeostasis <ref type="bibr" target="#b3">[4]</ref> .</s><s>With these conceptual considerations in mind clinical trials were initiated where fecal microbiota transplantation (FMT) served as treatment for UC.</s><s>In the 2 placebo-controlled, randomized trials, the primary endpoint was not met <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> .</s><s>Nevertheless, 2 observations were of interest for future developments: (1) the diversity of the intestinal microbiota increased in patients with an amelioration of disease (independent of the treatment arm) and ( <ref type="formula">2</ref>) the donor and hence the composition of the donor's intestinal microbiota seems to play a significant role <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> .</s><s>What are the conclusions drawn from these trials?</s><s>Will there be FMT for UC patients?</s><s>It is at this point very unlikely that FMT will enter routine treatment for UC patients; however, it is expected that a better defined microbiota-based therapy will play a role in future treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Induction of Remission</head><p><s>The first strategy to induce remission in UC is the administration of mesalazine in a systemic, local or even combined manner <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref> .</s><s>The key to success using this strategy is to use the maximum dose and take advantages of the combined systemic and local therapy <ref type="bibr" target="#b9">[9]</ref> .</s><s>If this is not resulting in the induction of remission, systemic steroids should be introduced.</s><s>In moderate disease, 40 mg/day might suffice in moderate to severe disease, and 1 mg/kg body weight becomes mandatory <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref> .</s><s>In a majority of cases, remission can be successfully introduced by applying this strategy.</s><s>If steroid-free remission cannot be induced, 2 scenarios are possible:</s></p><p><s>(1)The patient with this disease shows signs of recovery; however, the disease is steroid-dependent.</s><s>In this case, an immunosuppressive strategy is used for treatment.</s></p><p><s>As a first step and as part of this strategy, a thiopurine is used.</s><s>If this is not tolerated or is found to be ineffective, the integrin-antagonist, vedolizumab, or a TNFantibody are used as alternative treatment plans; this is discussed in more detail below.</s><s>(2)The disease is steroid refractory.</s><s>In this case, after trying steroid intravenously, 2 options are available: (1) the classic strategy cyclosporine is introduced <ref type="bibr" target="#b11">[10]</ref> or (2) a TNF-antibody that has been proven to be not inferior to cyclosporine treatment is administered <ref type="bibr" target="#b12">[11]</ref> .</s></p><p><s>In rare cases, till today, disease progresses faster than anticipated and cannot be controlled by any conservative strategy.</s><s>Under these circumstances, surgery is the preferred option.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Maintenance of Remission</head><p><s>The primary goal of medical therapy in remission of disease is to achieve a steroid-free condition.</s><s>As mentioned earlier, this can be maintained by mesalazine that can be administered either systemically or locally <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b9">[9]</ref> .</s><s>In case of mesalazine intolerance, the probiotic E. coli Nissle 1917 has been shown to be equally efficacious in maintaining remission <ref type="bibr" target="#b13">[12]</ref> .</s><s>If neither mesalazine nor E. coli Nissle 1917 treatment is able to taper steroids completely, a long-term immunosuppressive strategy should be introduced.</s><s>In the first step, a thiopurine will be introduced.</s><s>In case the patient fails to respond to thiopurine therapy, the administration of either TNF-antibodies or the integrin-antagonist vedolizumab can be chosen as the next course of treatment.</s><s>In selected cases, a combination therapy of a biological and thiopurine might be required.</s><s>Here, the UC Success trial could demonstrate an addi-tional effect by combining a thiopurine with infliximab when compared to either treatment alone <ref type="bibr" target="#b14">[13]</ref> .</s><s>If the medical strategies do not result in a reasonable life quality due to uncontrolled disease activity or due to side effects, surgery should be offered <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8]</ref> .</s></p><p><s>Figure <ref type="figure" target="#fig_0">1</ref> summarizes the currently approved therapeutic options for UC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recent Developments</head><p><s>Methotrexate has been proven effective for patients with Crohn's disease but was never evaluated in patients with UC.</s><s>The recent METEOR trial by the GETAID group fills this gap <ref type="bibr" target="#b15">[14]</ref> .</s><s>Here, patients with steroiddependent UC were randomly assigned to receive either placebo or methotrexate (25 mg/weekly) for 24 weeks.</s><s>The primary endpoint achieved was steroid-free remission as defined by a Mayo score ≤ 2 with no item &gt;1, hence including clinical as well as endoscopic features, and complete withdrawal of steroids at week 16.</s><s>In this trial, methotrexate was not superior to placebo in terms of the primary endpoint of the study <ref type="bibr" target="#b15">[14]</ref> .</s><s>Notably, one secondary endpoint was attained, namely, methotrexate-induced clinical remission without steroids at week 16.</s><s>However, all other 8 secondary endpoints were not achieved; hence, the overall results of this study underline that methotrexate is not efficacious in UC <ref type="bibr" target="#b16">[15]</ref> .</s></p><p><s>As already introduced above, the anti-integrin-strategy vedolizumab targeting α4β7 was introduced 2 years ago and is about to enter the next generation of guidelines in UC as well as with regard to Crohn's disease <ref type="bibr" target="#b17">[16,</ref><ref type="bibr" target="#b18">17]</ref> .</s><s>The integrin α4β7 enables the infiltration of immune cells into the intestinal wall and so represents an almost gut-specific approach <ref type="bibr" target="#b19">[18]</ref> .</s><s>By blocking α4β7 the therapeutic effect observed is mediated by the inhibition of the infiltration of inflammatory cells into the tissue; however, all inflammatory cells that had entered this site before can still mediate inflamma- tion.</s><s>The lifespan of these cells averages up to 60 days and this is the reason for a delayed onset of disease amelioration.</s><s>Nevertheless, this strategy is highly specific and entirely different with regard to the mechanism of action when compared, for example, to TNF-antibodies.</s><s>Hence, this strategy is a valuable addition to the toolbox of IBD therapy.</s><s>In line with this, the GEMINI trials indicate therapeutic efficacy for UC as well as Crohn's disease <ref type="bibr" target="#b17">[16,</ref><ref type="bibr" target="#b18">17]</ref> .</s><s>Although a different strategy, vedolizumab has been proven to be more effective in the treatment of TNF-antibody-naïve patients <ref type="bibr" target="#b17">[16,</ref><ref type="bibr" target="#b18">17]</ref> .</s><s>The main studies discussed above are summarized in table 1 .</s><s>In addition, figure <ref type="figure" target="#fig_2">3</ref> provides a gradual progression from health to severe inflammation in UC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Future Perspective for Novel Therapies</head><p><s>What novel strategies are on the horizon for UC? Within the class of vedolizumab, etrolizumab, which is a sole β7 antagonist, has shown efficacy in phase II trials and is currently being investigated in a broad phase III study program <ref type="bibr" target="#b20">[19]</ref> .</s><s>Etrolizumab represents just one out of numerous strategies pointing to this direction.</s><s>There is no doubt that vedolizumab will get additional members to this class over the next years.</s></p><p><s>Additionally, an entirely new class for UC is in view -the Janus kinase (Jak) inhibitors.</s><s>Tofacitinib has been investigated in 2 phase III randomized-controlled trials (OCTAVE) in UC.</s><s>Here, tofacitinib (10 mg b.i.d.) was tested in a 4: 1 randomization against placebo.</s><s>The primary endpoint was remission in week 8.</s><s>The primary endpoint in these trials was achieved and it showed again, similar to vedolizumab, that tofacitinib is more efficacious in patients who had not previously received TNF-antibodies <ref type="bibr" target="#b21">[20]</ref> .</s></p><p><s>Lastly, over a year ago, biosimilars for infliximab entered the market in Europe and therefore into clinical practice.</s><s>The biosimilar CT-P13 has been proven to exert similar efficacy in 2 randomized controlled trials for rheumatoid arthritis and ankylosing spondylitis <ref type="bibr" target="#b22">[21,</ref><ref type="bibr" target="#b23">22]</ref> and was subsequently approved for all other indications that infliximab had been previously approved.</s><s>It is beyond the scope of this article to enter the complex discussion of how to handle biosimilars in clinical practice.</s><s>For CT-P13, data obtained from real life are now available for UC, indicating, in fact, similar efficacy when compared to the original product <ref type="bibr" target="#b24">[23]</ref> .</s><s>Several questions yet remain unresolved as, for example, how we proceed with the next biosimilar for infliximab that already has received approval by the European authorities.</s><s>Can we switch in between different biosimilars in a patient frequently or should we rather stick on to one product?</s><s>Who will be able to dictate as to which biosimilar we will have to prescribe in the future?</s></p><p><s>With all these open questions, the physicians should better adhere to the facts; we need scientific proof and hence studies to answer these questions.</s><s>If answered, as it has been for the first biosimilar, there is no reason not to use it in clinical practice.</s><s>However, in our opinion, at this point one should stay with one product in a patient and avoid changing, since there is the fear of inducing neutralizing antibodies, thereby limiting clinical efficacy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Perspective</head><p><s>The content above indicates that after decades of stagnancy, several novel therapeutic strategies have either already entered clinical practice or are likely to enter in the foreseeable future.</s><s>This is posing novel challenges, since a broader variety of possibilities raise the question as to in which clinical situation and in which patient we should introduce which strategy.</s><s>A future therapeutic algorithm is shown in figure <ref type="figure" target="#fig_1">2</ref> .</s><s>Preliminary and rather experimental proof-of-concept studies for adalimumab and etrolizumab indicate that this is feasible.</s><s>The main task for the next years will be to restructure clinical algorithms and provide predictive markers that will guide the choice for each individual patient.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Key Points</head><p><s>(1) Environmental factors that are yet to be defined contribute to the pathogenesis of UC. (2) An accelerated step-up therapy represents the current standard in UC. (3) Anti-integrins represent the most recently introduced pharmacological class in the therapy of UC. (4) Novel strategies including Jak inhibitors are in the process of making a difference in the near future.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure Statement</head><p><s>B.S. has served as consultant for Abbvie, Janssen, Hospira, MSD, Mundipharma, Takeda and has received speaker fees from Abbvie, Falk, Ferring, Hospira, MSD, Takeda.</s><s>B.S. has received a grant from Hospira.</s><s>E.S. has no conflicts of interest.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>Currently approved medical treatment for patients with UC.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p><s>Fig. 2. Future perspective on individualized therapeutic algorithms for patients with UC.</s></p></div></figDesc><graphic coords="4,42.62,195.35,510.01,152.89" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc><div><p><s>Fig. 3. Colon mucosa -health and inflammation.</s><s>a Healthy mucosa, b mild inflammation, c severe inflammation.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Summary of relevant studies</s></p></div></figDesc><table><row><cell cols="2">Trial name Aim</cell><cell>Number</cell><cell>Primary endpoint</cell><cell>Results</cell><cell>p value</cell><cell>Author,</cell></row><row><cell></cell><cell></cell><cell>of patients</cell><cell></cell><cell></cell><cell></cell><cell>year</cell></row><row><cell>Meteor</cell><cell>Evaluate efficacy of</cell><cell>111</cell><cell>Steroid-free remission week</cell><cell>31.7% MTX versus</cell><cell>0.15</cell><cell>Carbonnel</cell></row><row><cell></cell><cell>parenteral methotrexate</cell><cell></cell><cell>16 (Mayo ≤2, no item &gt;1) and</cell><cell>19.6% placebo (95% CI</cell><cell></cell><cell>et al. [14],</cell></row><row><cell></cell><cell>(MTX) in steroid-dependent</cell><cell></cell><cell>complete steroid withdrawal</cell><cell>-4.0 to 28.1%)</cell><cell></cell><cell>2016</cell></row><row><cell></cell><cell>UC</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">UC success Evaluate the comparative</cell><cell>239</cell><cell>Corticosteroid-free clinical</cell><cell>39.7% infliximab +</cell><cell>0.017 combo</cell><cell>Panaccione</cell></row><row><cell></cell><cell>efficacy and safety of</cell><cell></cell><cell>remission at week 16</cell><cell>azathioprine versus</cell><cell>versus</cell><cell>et al. [13],</cell></row><row><cell></cell><cell>infliximab and azathioprine</cell><cell></cell><cell></cell><cell>22.1% infliximab versus</cell><cell>Infliximab</cell><cell>2014</cell></row><row><cell></cell><cell>therapy alone or in</cell><cell></cell><cell></cell><cell>23.7% azathioprine</cell><cell>0.032 combo</cell><cell></cell></row><row><cell></cell><cell>combination for UC</cell><cell></cell><cell></cell><cell></cell><cell>versus</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>azathioprine</cell><cell></cell></row><row><cell>-</cell><cell>Compare the efficacy and</cell><cell>115</cell><cell>Treatment failure defined by</cell><cell>60% ciclosporin versus</cell><cell>0.52</cell><cell>Laharie et</cell></row><row><cell></cell><cell>safety of infliximab and</cell><cell></cell><cell>the absence of clinical</cell><cell>54% infliximab (absolute</cell><cell></cell><cell>al. [11],</cell></row><row><cell></cell><cell>ciclosporin in patients with</cell><cell></cell><cell>response at day 7</cell><cell>risk difference 6%;</cell><cell></cell><cell>2012</cell></row><row><cell></cell><cell>acute severe UC</cell><cell></cell><cell></cell><cell>95% CI -7 to 19)</cell><cell></cell><cell></cell></row><row><cell>Gemini 1</cell><cell>Efficacy of vedolizumab in</cell><cell>374</cell><cell>Reduction of Mayo score of at</cell><cell>47.1% vedolizumab</cell><cell>&lt;0.001</cell><cell>Feagan</cell></row><row><cell></cell><cell>induction therapy</cell><cell></cell><cell>least 3 points and a decrease</cell><cell>versus 25.5% placebo</cell><cell></cell><cell>et al. [16],</cell></row><row><cell></cell><cell></cell><cell></cell><cell>of at least 30% from baseline;</cell><cell>(95% CI 11.6-31.7)</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>decrease in rectal bleeding</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>score of at least 1 point or an</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>absolute rectal bleeding</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>subscore of 0 or 1</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Digestion 2016;94:181-185 DOI: 10.1159/000452621</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci</title>
		<author>
			<persName><forename type="first">D</forename><surname>Ellinghaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jostins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Spain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="510" to="518" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Genome-wide meta-analysis increases to 71 the number of confirmed Crohn&apos;s disease susceptibility loci</title>
		<author>
			<persName><forename type="first">A</forename><surname>Franke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Mcgovern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Barrett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1118" to="1125" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Molodecky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Soon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Rabi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="46" to="54" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>e42; quiz e30</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">How colonization by microbiota in early life shapes the immune system</title>
		<author>
			<persName><forename type="first">T</forename><surname>Gensollen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Iyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Kasper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="page" from="539" to="544" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Moayyedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Surette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="102" to="109" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>e6</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Rossen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fuentes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Van Der Spek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="110" to="118" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>e4</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dignass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Lindsay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sturm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="991" to="1030" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Dignass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Preiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Aust</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Updated German guideline on diagnosis and treatment of ulcerative colitis</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Z Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="1276" to="1341" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Combined oral and enema treatment with</title>
		<author>
			<persName><forename type="first">P</forename><surname>Marteau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Probert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lindgren</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/ moderate active ulcerative colitis: a randomised, double blind, placebo controlled study</title>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="960" to="965" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Van Assche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Haens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Noman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="1025" to="1031" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><surname>Laharie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bourreille</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Branche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="page" from="1909" to="1915" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine</title>
		<author>
			<persName><forename type="first">W</forename><surname>Kruis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fric</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pokrotnieks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="1617" to="1623" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Panaccione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Middleton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="392" to="400" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>e3</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Carbonnel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Colombel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Filippi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">150</biblScope>
			<biblScope unit="page" from="380" to="388" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>e4</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">The METEOR trial: the burial of methotrexate in ulcerative colitis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Macaluso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Renna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cottone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="page" from="211" to="212" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Vedolizumab as induction and maintenance therapy for ulcerative colitis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Feagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rutgeerts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Sands</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="699" to="710" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Vedolizumab as induction and maintenance therapy for Crohn&apos;s disease</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Sandborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Feagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rutgeerts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="711" to="721" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Danese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Panés</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="981" to="989" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Vermeire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'byrne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Keir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">384</biblScope>
			<biblScope unit="page" from="309" to="318" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Efficacy and safety of oral tofacitinib as induction therapy in patients with mo derate-tosevere ulcerative colitis: results from 2 phase 3 randomised controlled trials</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Sandborn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Sands</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Haens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">S1</biblScope>
			<biblScope unit="page">P019</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study</title>
		<author>
			<persName><forename type="first">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hrycaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jeka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1605" to="1612" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Yoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hrycaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Miranda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1613" to="1620" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Farkas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rutka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Golovics</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Crohns Colitis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1273" to="1278" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
